Studien

SPACE Single-Arm Phase II-Study in Patients with extensive stage small cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide AIO-TRK-0119 · Rekrutierung beendet Studie anzeigen

AIO-SUP-0119ass Quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) in Germany [QS-SID) AIO-SUP-0119ass · Rekrutierung beendet Studie anzeigen

NIFE Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial AIO-YMO/HEP-0315 · Rekrutierung beendet Studie anzeigen

NintNivo Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology– An AIO phase Ib trial AIO-TRK-0117 · Rekrutierung beendet Studie anzeigen

INTEGA Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma AIO-STO-0217 · Rekrutierung beendet Studie anzeigen

RAMONA A multicenter open-label phase II trial to evaluate nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer AIO-STO-0117 · Rekrutierung beendet Studie anzeigen

PREDICT Second line therapy with Nal-IRI after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st line therapy AIO-PAK-0216 · Rekrutierung beendet Studie anzeigen

PANTHEON A health service research study to investigate survival of metastatic pancreatic cancer patients after sequential chemotherapy: An AIO phase II cross over trial AIO-PAK-0116 · Rekrutierung beendet Studie anzeigen

OPTIM A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck AIO-KHT-0117 · Rekrutierung beendet Studie anzeigen

ELDORANDO Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers (ELDORANDO) AIO-KHT-0115 · Rekrutierung beendet Studie anzeigen